A large impairment charge for a failed diabetes trial pushed Evotec AG into a loss for 2014 in what was otherwise a year of higher revenue and expanding business opportunities. Impairment charges of €8.5 million gave rise to an operating loss of €6.4 million for the year and a net loss of €7 million.
